New to Bioss? Enjoy 35% of your first order. Use code "FirstOrder35" - Offer valid for new U.S. Customers on direct orders only

MAPKAPK5(Ser93) Polyclonal Antibody, RBITC Conjugated

Applications

  • WB
  • IF(IHC-P)
  • IF(IHC-F)
  • IF(ICC)

Reactivity

  • Human
  • Mouse
  • Rat

Predicted Reactivity

  • Dog
  • Cow
  • Horse
  • Chicken
Overview
Catalog # bs-5505R-RBITC
Product Name MAPKAPK5(Ser93) Polyclonal Antibody, RBITC Conjugated
Applications WB, IF(IHC-P), IF(IHC-F), IF(ICC)
Reactivity Human, Mouse, Rat
Predicted Reactivity Dog, Cow, Horse, Chicken
Specifications
Conjugation RBITC
Host Rabbit
Source KLH conjugated synthetic phosphopeptide derived from human MAPKAPK5 around the phosphorylation site of Ser93
Modification Site Ser93
Clonality Polyclonal
Isotype IgG
Concentration 1ug/ul
Purification Purified by Protein A.
Storage Buffer Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Storage Condition Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.
Target
Gene ID 8550
Subcellular location Cytoplasm, Nucleus
Synonyms MAPKAPK5phospho S93; MAP kinase-activated protein kinase 5; MAPKAP kinase 5; MAPKAPK5; mitogen-activated protein kinase-activated protein kinase 5; p38-regulated/activated protein kinase.
Background The serine/threonine kinase PRAK is activated in response to cellular stress and proinflammatory cytokines, through its phosphorylation by MAP kinases including MAPK1/ERK, MAPK14/p38 alpha, and MAPK11/p38 beta. PRAK has been reported to have a putative tumor suppressor function by mediating senescence upon activation by p38 in response to oncogenic ras. It is thought that phosphorylation of p53 by PRAK following activation of p38 MAPK by ras plays an important role in ras induced senescence and tumor suppression.
Application Dilution
WB 1:300-5000
IF(IHC-P) 1:50-200
IF(IHC-F) 1:50-200
IF(ICC) 1:50-200